Profil Penggunaan Kortikosteroid Sistemik untuk Terapi Sindrom Stevens Johnson (SSJ) – Nekrolisis Epidemal Toksik (NET) di Instalasi Rawat Inap RSUD DR. Moewardi Surakarta, Indonesia - Januari 2016 -Desember 2017
DOI:
https://doi.org/10.55175/cdk.v48i4.61Keywords:
kortikosteroid, SSJ-NETAbstract
Latar belakang: Nekrolisis epidermal disebut Sindrom Stevens Johnson (SSJ) apabila yang terlibat kurang dari 10% dari area tubuh, 10% sampai 29% disebut SSJ overlap NET, dan lebih dari 30% disebut NET. Tujuan: Untuk mengetahui gambaran umum pasien SSJ-NET serta penggunaan kortikosteroid sistemik di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta periode Januari 2016 – Desember 2017. Metode: Studi deskriptif retrospektif dengan populasi dan sampel penelitian pasien rawat inap di Instalasi Rawat Inap RSUD Dr. Moewardi, Surakarta, periode Januari 2016 – Desember 2017. Sampel menggunakan data sekunder dari status rekam medis di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta. Hasil: Total pasien 26 orang terutama berusia 46 – 55 tahun dan 56 – 65 tahun (23%). Laki-laki lebih banyak (57%). Diagnosis SSJ (61%) terbanyak dibandingkan SSJ overlap NET (19%) ataupun NET (19%). Hipertensi sebagai penyakit penyerta terbanyak (15%). Keterlibatan mukosa terbanyak pada mulut (88 %) dan penyebab terbanyak SSJ-NET melibatkan lebih dari satu macam obat (53%). Obat penyebab yang dicurigai terutama adalah antibiotik golongan sefalosporin dan parasetamol (23%). Rerata lama terapi deksametason adalah 10 hari dengan dosis rata-rata 25 mg per hari. Simpulan: Pengobatan kortikosteroid sistemik pada kasus SSJ – NET di RSUD dr. Moewardi Surakarta pada umumnya menghasilkan perbaikan klinis dengan rata-rata perawatan 10 hari dan dosis rata-rata deksametason 25 mg per hari.
Background: Epidermal Necrolysis is classified into several degree of severity based on the area of the body involved, below 10% is SJS, 10% - 29% is SJS overlap TEN, and 30% is TEN. Objective: To provide general description of SJS-TEN patients and systemic corticosteroids therapy in Dr. Moewardi General Hospital Surakarta January 2016 - December 2017. Methods: A retrospective descriptive study on in-patients in Dr. Moewardi General Hospital Surakarta between January 2016 and December 2017. Results: Total sample was 26 patients, mostly male (57%) in 46 - 55 years old and 56 - 65 year-old (23%). The most common diagnosis was SJS (61%) followed by SJS overlap TEN (19%) and TEN (19%). Hypertension was the most frequent comorbid disease (15%). Mostly affected was mouth mucosa (88%) and caused by mostly more than one drug (53%). Suspected causative drugs were mostly cephalosporin and paracetamol (23%). The average duration of dexamethason therapy was 10 days with an average dose 25 mg per day. Conclusion: SSJ - NET cases in Dr. Moewardi General Hospital Surakarta were mostly treated with systemic corticosteroids for an average of 10 days and an average dose of dexamethason 25 mg per day.
Downloads
References
Roujeau JC AL. Epidermal necrolysis. In: Fitzpatrick’s dermatology in general medicine. 1st Ed. New York: Mc Graw Hill; 2012 .p. 439-48.
Stocka-Labno E, Gabzdyl N, Misiak-galazka M, Pawlowska-Kisiel M, Lazowsk T, Rudnicka L. Stevens – johnson syndrome and toxic epidermal necrolysis in an academic hospital setting: A 5-year retrospective study. Our Dermatology Online. 2016;7(4):381-4.
Habif T. Stevens johnson syndrome/toxic epidermal necrolysis spectrum of disease. In: Clinical dermatology. 6th Ed. Hanover USA: Elsevier; 2016 .p. 717-23.
Huang CH, Ho JC, Cheng YW, Wu WM, Huang SL, Wang CY. Epidemiological study of stevens-johnson syndrome and toxic epidermal necrolysis: Retrospective analysis of Southern Taiwanese population during 2002 to 2007. Dermatol Sin. 2008;27:15-26.
Thaha MA. Sindrom stevens-johnson dan nekrolisis epidermal toksis di RSUP MH Palembang periode 2006 -2008. Media Med Indones. 2009;43(5):234-9.
Hastuti R, Ulya I, Irawanto ME. Hubungan antara SCORTEN dengan terjadinya mortalitas pada pasien SSJ/NET di instalasi rawat inap RSUD dr. Moewardi Surakarta. Surakarta; 2016.
Maciejewska J, Jankowski M, Zegarska B, Czajkowski R. Stevens-johnson syndrome / toxic epidermal necrolysis presumably induced by norfloxacin. Postep Dermatologii i Alergol. 2014;3:194-7.
Gupta LK, Martin AM, Agarwal N, D'Souza P, Das S, Kumar R, et al. Guidelines for the management of stevens – johnson syndrome / toxic epidermal necrolysis : An Indian perspective. Indian J Dermatol Venereol Leprol. 2016;82(6):603-25.
Venkateshwarlu M, Radhika B. Diagnosis and management of drug-induced stevens-johnson syndrome : Report of two cases. J Indian Acad Oral Med Radiol. 2011;23(3):429-33.
Fbb Y, Wahiduzzaman M, Pubalan M. Stevens - johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Sarawak: A four years’ review abstract. Egypt Dermatol Online J. 2008;4(1):1-13.
Ferrandiz-Pulido C, Garcia-Patos V. A review of causes of stevens – johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013;98:998-1003.
Kim H, Kim S, Park GY, Kwon EG, Kim HH, Jeong JY, et al. Causes and treatment outcomes of stevens-johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med. 2012;27(2):203-10.
Kariosentono H. Sindroma stevens johnson dan nekrolisis epidermal toksika (NET). In: Mochtar M, ed. Penyakit kulit gawat darurat. 1st ed. Surakarta: UPT. Penerbitan dan Percetakan UNS; 2015 .p. 1-31.
Roongpisuthipong W, Prompongsa S, Klangjareonchai T. Retrospective analysis of corticosteroid treatment in stevens-johnson syndrome and/or toxic epidermal necrolysis over a period of 10 years in Vajira hospital, Navamindradhiraj University, Bangkok. Dermatol Res Pract. 2014;2014:1-5.
Su S, Chung W. Update on pathobiology in stevens-johnson syndrome and toxic epidermal necrolysis. Dermatol Sin. 2013;31(4):175-80.
Prins CF LE. Erythema multiforme, stevens johnson syndrome and toxic epidermal necrolysis. In: Bolognia JL, editor. Dermatology. 3rd Ed. Spain; 2012 .p. 323–33.
Yim H, Park JM, Cho YS, Kim D, Hur J, Chun W, et al. A clinical study of stevens-johnson syndrome and toxic epidermal necrolysis: Efficacy of treatment in burn intensive care unit. J Korean Surg Soc. 2010;78(3):133-9.
Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for stevens-johnson syndrome / toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8.
Hirahara K, Kano Y, Sato Y, Horie C, Okazaki A, Ishida T, et al. Methylprednisolone pulse therapy for stevens-johnson syndrome/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkers. J Am Dermatol. 2013;69(3):496-8.
Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, dkk. Toxic epidermal necrolysis: Analysis of clinical course and SCORTEN - Based comparison of mortality rate and treatment modalities in Korean patient. Acta Dermatol Venereol. 2005;85(6):497-502.
Del JQ, Michaels B, Rosso JQ Del. The role of systemic corticosteroid therapy in erythema multiforme major and stevens-johnson syndrome A review of past and current opinions. J Clin Aesthetic Dermatol. 2009;2(3):51-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
